Clinical Study Evaluating Selective or Nonselective Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis
Who is this study for? Patients with primary osteoporosis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:
• • Male \& female osteoporotic patient aged ≥ 50 years
‣ Hypertensive \& normotensive patients
⁃ BMD T-score ≥ 2.5 or more SD below peak bone mass
Locations
Other Locations
Egypt
Sherief Abd-Elsalam
RECRUITING
Tanta
Contact Information
Primary
Sherief Abd-Elsalam, ass. prof.
sheriefabdelsalam@yahoo.com
00201147773440
Time Frame
Start Date: 2017-10-01
Estimated Completion Date: 2030-10-01
Participants
Target number of participants: 50
Treatments
Experimental: nonselective beta blocker group
Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to propranolol (Inderal®) 10 mg once daily titrated as patient's response.
Experimental: cardio-selective beta blocker group
Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to bisoprolol (Concor®) 5 mg once daily titrated as patient's response.
Placebo_comparator: Control group
Ten patient with osteoporosis on alendronate sodium 70 mg (Fosamax®) once/week, vitamin D3 1 mcg once daily and calcium supplement 500 mg once daily.
Related Therapeutic Areas
Sponsors
Leads: Sherief Abd-Elsalam